Ontology highlight
ABSTRACT:
SUBMITTER: Greenspan SL
PROVIDER: S-EPMC7515468 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Greenspan Susan L SL Fitzpatrick Lorraine A LA Mitlak Bruce B Wang Yamei Y Harvey Nicholas C NC Deal Chad C Cosman Felicia F McClung Michael M
Menopause (New York, N.Y.) 20201001 10
<h4>Objective</h4>Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVExtend. We postulated that similar improvements in bone mineral density and safety would be demonstrated in women ≥80 years.<h4>Methods</h4>Post hoc analyses of bone mineral density and fracture ...[more]